NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 7 February 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Dr Peter Baker-Gulliver Items 1 to 4.2.2
4. Richard Ballerand Present for all items
5. Dr Justin Daniels Present for all items
6. Ana Duarte Present for all items
7. Dr Steve Edwards Items 5 to 5.3.2
8. Mohamad Farhat Present for all items
9. Dr Fiona MacPherson Smith Present for all items
10. Professor G.J. Melendez-Torres Items 1 to 4.2.2
11. Dr Pratheeban Nambyiah Items 1 to 4.2.2
12. Becky Pennington Present for all items
13. Dr Mohit Sharma Present for all items
14. Alan Thomas Present for all items
15. Min Ven Teo Present for all items
16. Jacqueline Tomlinson (Observer) Present for all items
17. Malcolm Oswald Items 1 to 4.2.2
18. Stella O’Brien Items 5 to 5.3.2

NICE staff (key players) present

Janet Robertson, Associate Director Items 1 to 4.2.2

Richard Diaz, Associate Director Items 5 to 5.3.2

Thomas Feist, Project Manager Items 1 to 4.2.2

Daniel Davies, Project Manager Items 5 to 5.3.2

Eleanor Donegan, Health Technology Assessment Adviser Items 1 to 4.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 4 to 4.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 5 to 5.3.2

Sharlene Ting, Health Technology Assessment Analyst Items 1 to 4.2.2

Harsimran Sarpal, Health Technology Assessment Analyst Items 5 to 5.3.2

Adam Storrow, Business Analyst, RIA Present for all Items

Rachael Cazaly, Senior Medical Editor Items 1 to 4.2.2

Olivia Waring, Senior Medical Editor Items 5 to 5.3.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.2.2

Carl Jackson, Assistant Project Manager, COT Items 1 to 4.2.2, 5.1.3 to 5.3.2

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3, 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3

Denise Moyo, Coordinator, COT Present for all Items

Marcia Miller, Administrator, TA Items 1 to 4.2.2

Wajeeha Asim, Administrator, TA Items 5 to 5.3.2

NICE staff (observers) present

Hannah Patrick, Consultant Clinical Adviser, Managed Access team Items 5 to 5.3.2

External assessment group representatives present

Tracey Jhita, BMJ Group, items 1 to 4.1.3

Ben Farrar, BMJ Group, items 1 to 4.1.3

Madhusubramanian Muthukumar, Peninsula Technology Assessment Group (Pen-TAG), items 5 to 5.2.1

Professor G.J. Melendez-Torres, Peninsula Technology Assessment Group (Pen-TAG), items 5 to 5.2.1

Clinical, Patient & NHS England experts present

Dr Abby Macbeth, Consultant Dermatologist, clinical expert, nominated by British Association of Dermatologists, items 1 to 4.1.3

Dr Matthew Harries, Consultant Dermatologist, clinical expert nominated by British Association of Dermatologists, items 1 to 4.1.3

Sue Schilling, Chief Executive Officer, patient expert nominated by Alopecia UK, items 1 to 4.1.3

Lynn Wilks, Trustee and volunteer, patient expert nominated by Alopecia UK, items 1 to 4.1.3

Dr David Jackson, Consultant Physician; Head, Guy’s Severe Asthma Centre; Reader in Respiratory Medicine, clinical expert nominated by AstraZeneca, items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Professor Abdallah Al-Mohammed, Andrew Champion, Dr Craig Buckley, Dr David Maudgil, Dominic Pivonka, Hugo Pedder, Dr Louis Choo.

### News and announcements

* 1. .

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 10 January 2023.

### Appraisal of Baricitinib for treating severe alopecia areata [ID3979]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly & Company Limited.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Steve Edwards declared a non-financial professional interest as he is a member of the EAG that assessed Baricitinib for treating severe alopecia areata [ID3979]. It was agreed that his declaration would prevent Dr Steve Edwards from participating in discussions on this appraisal.
* Prior to the meeting, Dominic Pivonka declared a direct financial interest as his employer (AbbVie) has a medicine which is a competitor to baricitinib in other therapy areas (rheumatoid arthritis and atopic dermatitis). It was agreed that his declaration would prevent Dominic Pivonka from participating in discussions on this appraisal.
* Lynn Wilks declared an indirect financial interest as her organisation Alopecia UK, has corporate sponsorships/memberships from Eli lily and concert Pharma, aswell as winning a research grant from Pfizer. It was agreed that her declaration would not prevent Lynn Wilks from providing expert advice to the committee.
* Sue Schilling declared an indirect financial interest as her organisation Alopecia UK, has corporate sponsorships/memberships from Eli lily and concert Pharma, aswell as winning a research grant from Pfizer. Prior to the meeting, She also declared a direct non-financial interest as Alopecia UK are a patient body advocating for people affected by multiple types of alopecia. It was agreed that these declarations would not prevent Sue Schilling from providing expert advice to the committee.
* Dr Abby Macbeth declared an indirect interest as she works as the NIHR regional researcher and is part of the guideline group for BAD for alopecia areata. She also declared a direct non-financial interest as she has also co-authored epidemiology papers with a team from Pfizer but no payment was received, and has done charitable work for the UK dermatology clinical trials network and alopecia UK committee. It was agreed that these declarations would not prevent Dr Abby Macbeth from providing expert advice to the committee.
* Dr Matthew Harries declared a direct financial interest as he has conducted consultancy work with Pfizer and Eli Lilly discussing treatment practices and outcome measures for AA in UK. He also declared and indirect interest as he is a local PI RCT Soterios for a topical treatment on AA. Prior to the meeting, Dr Matthew Harries also declared a direct financial interest as he is co-director of MJHarries Dermatology Ltd and declared direct non-financial interests as he is co-author on a meeting abstract exploring PRO corelation with disease severity in AA and co-author NEJM Editorial on the Phase 3 baricitinib trials in AA. He also declared indirect interests prior to the meeting as he is a committee member for Alopecia UK, British Skin Foundation and is also a committee lead for the BAD alopecia areata guidelines update Also Dr Matthew Harries also stated prior to the meeting that he is the co-lead for the NIHR Manchester BRC Inflammatory hair diseases programme. It was agreed that these declarations would not prevent Dr Matthew Harries from providing expert advice to the committee.
* Ben Farrar declared a direct financial interest as he was employed by a Costello Medical who are a consultancy involved in the submission of this topic between September 2020 – December 2020 and November 2021 – May 2022, but did not work on Baricitinib or other comparators. It was agreed that his declaration would not prevent Ben Farrar from participating in the committee meeting.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Peter Baker-Gulliver (Clinical), Min Ven Teo (Cost), and Alan Thomas (Lay).
	1. Part 2 – Closed session (company representatives, clinical and patient, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10941>.

### Appraisal of Tezepelumab for treating severe asthma [ID3910]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca UK Ltd.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dominic Pivonka declared a direct financial interest as his employer (AbbVie) has a medicine in a different therapy area (atopic dermatitis) which is a competitor to one of the comparators (dupilumab) in this appraisal. It was agreed that his declaration would prevent Dominic Pivonka from participating in discussions on this appraisal.
* David Jackson declared a direct financial interest as he works with all the main drug companies for educational events and has received speaker fees from many pharmaceutical companies which include AstraZeneca who are the part owner of Tezepelumab. It was agreed that his declaration would not prevent David Jackson from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the vice chair.
	1. Part 2a – Closed session (company representatives, clinical experts and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10796>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 7 March 2023 and will start promptly at 9am.